Publications by authors named "Alexander Montenegro"
Article Synopsis
- The study aimed to compare the quality of life (QOL) between standard chemoradiotherapy (SFX) and altered fractionation radiotherapy (AFX) combined with the drug panitumumab (PMab) for patients with squamous cell head-neck carcinoma.
- It involved 320 patients and assessed their QOL using various questionnaires at different intervals, but after one year, no significant difference in QOL changes was observed between the two treatment arms.
- The results concluded that PMab with AFX did not lead to any lasting improvements in QOL or swallowing when compared to SFX with cisplatin.
Article Synopsis
- The Canadian Cancer Trials Group study HN.6 is a major clinical trial comparing two treatments for advanced squamous cell carcinoma of the head and neck, focusing on the use of anti-EGFR antibodies alongside radiotherapy versus standard chemoradiotherapy.
- The trial involved 320 patients across 17 centers and aimed to assess progression-free survival (PFS) between two treatment regimens: standard-fractionation radiotherapy with cisplatin and accelerated-fractionation radiotherapy with panitumumab.
- Results showed that both treatment arms had similar 2-year PFS rates (73% for cisplatin and 76% for panitumumab) and overall survival rates (85% for cisplatin and 88%
Background/aims: Understanding the influence or impact of epidemiological factors on cancer outcomes in clinical trials can broaden our knowledge of disease, trial populations and therapeutic effects thus leading to improved patient care. However, there is a lack of data on cancer patients' compliance with an epidemiology questionnaire in the context of a clinical trial.
Patients And Methods: Cancer patients were provided with a hypothetical scenario and surveyed regarding their willingness and preferences to complete an epidemiology questionnaire if incorporated into a cancer therapy trial.